Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in CMV infection compared with ganciclovir or valganciclovir (low certainty).
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).
Valaciclovir showed no clear difference in graft loss compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in leucopenia compared with ganciclovir or valganciclovir (moderate certainty).